At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 186 enrolled
Drug / intervention
Botulinum toxin type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus
In Brief
A Phase 2 clinical trial evaluating Botulinum toxin type A and Placebo for Hallux Abducto Valgus. Completed, enrolled 186 participants across 29 sites.
Detailed Summary
The purpose of this study is to investigate the efficacy and safety of treatment with multiple doses of Dysport in adults suffering from clinically significant pain associated with HAV who have not undergone surgery for their condition.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHallux Abducto Valgus
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedJun 2018
Primary CompletionDec 2019
Study CompletionMay 2020
TodayJul 2026
First PostedJun 26, 2018
Enrollment StartJun 19, 2018
Primary CompletionDec 17, 2019
Study CompletionMay 22, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.0 years ago
Interventions
Botulinum toxin type Abiological
Investigators will inject the reconstituted solution into foot muscles.
Placebodrug
Investigators will inject the reconstituted solution into foot muscles.